Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort

Journal of Viral Hepatitis

Volumn 22, Issue 12, 2015, Pages 1020-1032

  Doyle, J S ^a,b,c   Deterding, K ^d,e   Grebely, J ^f   Wedemeyer, H ^d,e,g   Sacks Davis, R ^a,b   Spelman, T ^a   Matthews, G ^f   Rice, T M ^h   Morris, M D ^h   McGovern, B H ⁱ   Kim, A Y ^j   Bruneau, J ^k   Lloyd, A R ^l   Page, K ^h   Manns, M P ^d,e,g   Hellard, M E ^a,b,c   Dore, G J ^f  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e Hep Net: German Network of Competence on Viral Hepatitis   (Germany)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

acute infection; hepatitis C virus; recently acquired infection; virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; HOST FACTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; ETHNICITY; FEMALE; GENE; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IFNL4 GENE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; AUSTRALIA; CANADA; CLINICAL TRIAL; COINFECTION; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; GENETICS; GERMANY; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT OUTCOME; UNITED STATES; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; AUSTRALIA; CANADA; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84945495702     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12429     Document Type: Article

References (40)

1. Hajarizadeh B, Grebely J, Dore GJ,. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10 (9): 553-562.
2. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al,. Effective treatment of injecting drug users with recently acquired Hepatitis C virus Infection. Gastroenterology 2010; 138: 123-135.
3. Deterding K, Gruner N, Buggisch P, Wiegand J, Galle PR, Spengler U, et al,. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 2013; 13 (6): 497-506.
4. Grebely J, Matthews GV, Dore GJ,. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8 (5): 265-274.
5. Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME,. Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 2013; 75 (4): 931-943.
6. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al,. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014; 59 (1): 109-120.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60 (2): 392-420.
8. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al,. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45 (2): 164-171.
9. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 7262: 399-401.
10. Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, et al,. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52 (4): 1216-1224.
11. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al,. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139 (5): 1586-1592, 92 e1.
12. Grebely J, Morris MD, Rice TM, Bruneau J, Cox AL, Kim AY, et al,. Cohort profile: the International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. Int J Epidemiol 2013; 42 (6): 1649-1659.
13. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801.
14. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al,. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138 (4): 1338-1345, 45 e1-7.
15. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al,. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37 (1): 60-64.
16. Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, et al,. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005; 40 (7): 951-958.
17. Busch MP,. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol 2001; 8 (3): 200-206.
18. Page-Shafer K, Pappalardo BL, Tobler LH, Phelps BH, Edlin BR, Moss AR, et al,. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol 2008; 46 (2): 499-506.
19. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al,. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43 (2): 250-256.
20. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME,. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat 2007; 14 (3): 213-220.
21. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al,. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139 (1): 120-129.
22. Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Feld JJ, et al,. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS 2012; 26 (13): 1653-1661.
23. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, et al,. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009; 48: 650-658.
24. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT,. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010; 17 (3): 201-207.
25. Grebely J, Matthews GV, Petoumenos K, Dore GJ,. Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection. J Viral Hepat 2010; 17 (12): 896.
26. Thomson EC, Fleming VM, Main J, Klenerman P, Weber J, Eliahoo J, et al,. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011; 60 (6): 837-845.
27. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H,. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 2004; 73 (3): 387-391.
28. Micallef JM, Kaldor JM, Dore GJ,. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13 (1): 34-41.
29. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al,. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007; 196 (10): 1474-1482.
30. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al,. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200 (8): 1216-1226.
31. Kawaoka T, Hayes CN, Ohishi W, Ochi H, Maekawa T, Abe H, et al,. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011; 54 (3): 408-414.
32. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al,. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139 (3): 821-827, 7 e1.
33. Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, et al,. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J Viral Hepat 2013; 20 (1): 59-64.
34. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
35. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al,. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357 (2): 124-134.
36. Kau A, Vermehren J, Sarrazin C,. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49 (4): 634-651.
37. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405-2416.
38. Vezali E, Aghemo A, Colombo M,. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32 (13): 2117-2138.
39. Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, et al,. Acute hepatitis C: a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology 2014; 59 (6): 2101-2109.
40. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al,. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Eng J Med 2004; 351 (5): 438-450.